undamentalytics Newsletter
Sign in

Viridian Therapeutics, Inc.\de (VRDN) stock

Add to watchlist

Add holding +

NASDAQ: VRDN Nasdaq Biotechnology Next results ~November 4, 2026

D Fundamentals grade

Viridian Therapeutics, Inc.\de is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$15

Valuation models combined (2)

Base case. Range ~$6.4–$17. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Viridian Therapeutics, Inc.\de valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling1 purchase and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds140 adding, 104 cuttingOf 56 active managers that changed their stake, 28 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Viridian Therapeutics files

Where Viridian Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $71m, up 23220.3% on a year earlier, slower than the 23382.8% growth a quarter earlier. That growth ranks 2 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -471.0% from -101507.9% a year earlier. Operating margin widened to -569.7% from -121831.1%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 7 financial-health checks.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Viridian Therapeutics, Inc.\de's trailing-twelve-month revenue grew 23220.3% year on year, with a free-cash-flow margin of -471.0%. Where it stands out: revenue growth of 23220.3% ranks 2 of 172 biotechnology companies we cover. Where it lags: change in growth rate of -162.5pp ranks 163 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 23220.3% (-162.5pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 23220.3% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 121261.5 points on a year ago.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 162.5 points lower than a quarter earlier.
  • Loss-making. Operating margin is -569.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -471.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 75.4% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 42.0% in a year.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$1.05 against an average estimate of -$1.03: missed by 2.3%
Revenue
$0m, up 278.7% on a year earlier
Share reaction
+12.0% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$1.02

Viridian Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.6%
  • 1 week+8.4%
  • 1 month+30.4%
  • This year-18.7%
  • 1 year+7.1%
  • 5 years+41.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$71.1M
Operating margin
-569.7%
Net margin
-544.1%

Growth

Revenue growth
+23220.3%
Change in growth rate
−162.5 pts

Cash

Free cash flow (TTM)
-$335M
FCF margin
-471.0%
Stock pay % of revenue
75.4%

Earnings

Last results
August 6, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Viridian Therapeutics, Inc.\de valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Viridian Therapeutics, Inc.\de as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$17 ~$11–$23 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.4 ~$6.6–$24 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$15 ~$6.4–$17 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Viridian Therapeutics, Inc.\de with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201520162017201820192020202120222023
Share price$168.30$75.15$156.45$45.45$7.20$16.45$19.77$29.21$21.78
Market value$6m$3m$201m$90m$15m$59m$236m$937m$975m
+ Net debt (− = net cash)−$21m−$17m−$37m−$20m−$13m−$46m−$42m−$151m−$83m
Enterprise value−$15m−$14m$163m$69m$2m$13m$193m$786m$892m
Multiples
Price / sales 1.1x0.9x50.1x10.7x3.4x55.7x79.5xn/mn/m
Price / earnings —————————
Price / free cash flow —————————
EV / EBITDA —————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Viridian Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -57.1% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -3247.1%; its worst year was -121831.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -1415.2% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 6462.8% over five years; stock-based pay has been a median 241.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $5m and EPS of −$1.02 (range −$1.26 to −$0.78) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.92 −18% $24m −66%
Next −$2.71 +31% $238m +878%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +3.3% on 90 days ago. In the last 30 days, 1 analyst raised Viridian Therapeutics, Inc.\de's forecast and 0 cut it.

Consensus EPS forecast Viridian Therapeutics, Inc.\de, last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.80 Current fiscal year, 60 days ago: −$3.95 Current fiscal year, 30 days ago: −$3.93 Current fiscal year, 7 days ago: −$3.94 Current fiscal year, Now: −$3.92 −$3.92 Next fiscal year, 90 days ago: −$2.63 Next fiscal year, 60 days ago: −$2.77 Next fiscal year, 30 days ago: −$2.75 Next fiscal year, 7 days ago: −$2.75 Next fiscal year, Now: −$2.71 −$2.71

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.80−$2.63
60 days ago −$3.95−$2.77
30 days ago −$3.93−$2.75
7 days ago −$3.94−$2.75
Now −$3.92−$2.71

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.03 −$1.05 −2.3%
Mar 2026 −$1.08 −$0.90 +16.3%
Dec 2025 −$1.00 −$1.08 −8.0%
Sept 2025 −$0.94 −$0.34 +63.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

17 analysts, Oct 2026
Buy17100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202631417
  2. Sep 202631417
  3. Aug 202631417
  4. Jul 202631417

Counts of recommendations published by analysts covering Viridian Therapeutics, Inc.\de, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.5%
of tradable shares
Days to cover
8.44
at average volume
Short interest, 1 month
−8%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.2%
of shares
Employees
252
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +7.1%

$23.63 on October 31, 2025 to $25.30

ThenNowEffect
Revenue (last 12 months) $305000 $71m +23220.3%
P/S multiple n/m 26.1x −99.5%
Share count 73m 73m 0.0%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
VRDN+20%+48%−25%−12%+62%−19%
Industry peers (median)−36%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
VRDN67%50%33%25%75%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
VRDN−57%−54%−70%−51%−47%−61%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 98% from January 10, 2017 to March 19, 2020. Getting back needed a 4715% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$13.30 – $33.78
From 52-week high
−25.1%
vs 50-day average
+16.7%
vs 200-day average
+16.5%
Volatility (1 year)
72%
Beta vs S&P 500
0.98

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±9.1%
After a week
5 up, 7 down
typical move ±8.8%
After a month
6 up, 6 down
typical move ±15.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +12.0% +0.5% +4.4% +8.8%
May 5, 2026 +24.7% +2.2% +19.9% +17.9%
February 26, 2026 +1.5% −1.0% −0.2% −5.4%
November 5, 2025 +22.0% −0.7% +28.3% +42.0%
October 21, 2025 −9.1% −0.5% −3.8% +19.1%
August 6, 2025 −5.2% +0.7% +8.1% +7.3%
May 6, 2025 −6.3% −0.4% −2.4% +8.5%
February 27, 2025 0.0% −0.1% +2.3% −7.0%
November 12, 2024 −12.6% −0.3% −21.3% −30.0%
August 8, 2024 −2.5% +2.8% −3.1% −7.9%
May 8, 2024 −8.1% +0.6% −5.7% −19.6%
February 27, 2024 +4.7% +0.1% −6.0% −9.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Viridian Therapeutics, Inc.\de in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Viridian Therapeutics, Inc.\de
$0 $20M $40M $60M $80M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $347K Revenue (TTM), FY23 Q4: $314K Revenue (TTM), FY24 Q1: $288K Revenue (TTM), FY24 Q2: $288K Revenue (TTM), FY24 Q3: $302K Revenue (TTM), FY24 Q4: $302K Revenue (TTM), FY25 Q1: $302K Revenue (TTM), FY25 Q2: $305K Revenue (TTM), FY25 Q3: $70.8M Revenue (TTM), FY25 Q4: $70.8M Revenue (TTM), FY26 Q1: $70.9M Revenue (TTM), FY26 Q2: $71.1M $71.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $347K
FY23 Q4 $314K
FY24 Q1 $288K
FY24 Q2 $288K
FY24 Q3 $302K
FY24 Q4 $302K
FY25 Q1 $302K
FY25 Q2 $305K
FY25 Q3 $70.8M
FY25 Q4 $70.8M
FY26 Q1 $70.9M
FY26 Q2 $71.1M
Revenue growth, TTM YoY Viridian Therapeutics, Inc.\de
-10000% 0% 10000% 20000% 30000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -81.6% Revenue growth, TTM YoY, FY23 Q4: -82.3% Revenue growth, TTM YoY, FY24 Q1: -82.6% Revenue growth, TTM YoY, FY24 Q2: -80.4% Revenue growth, TTM YoY, FY24 Q3: -13.0% Revenue growth, TTM YoY, FY24 Q4: -3.8% Revenue growth, TTM YoY, FY25 Q1: 4.9% Revenue growth, TTM YoY, FY25 Q2: 5.9% Revenue growth, TTM YoY, FY25 Q3: 23340.1% Revenue growth, TTM YoY, FY25 Q4: 23359.9% Revenue growth, TTM YoY, FY26 Q1: 23382.8% Revenue growth, TTM YoY, FY26 Q2: 23220.3% 23220.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -81.6%
FY23 Q4 -82.3%
FY24 Q1 -82.6%
FY24 Q2 -80.4%
FY24 Q3 -13.0%
FY24 Q4 -3.8%
FY25 Q1 4.9%
FY25 Q2 5.9%
FY25 Q3 23340.1%
FY25 Q4 23359.9%
FY26 Q1 23382.8%
FY26 Q2 23220.3%
Operating margin (TTM) Viridian Therapeutics, Inc.\de
-150000% -100000% -50000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -66869.7% Operating margin (TTM), FY23 Q4: -81035.0% Operating margin (TTM), FY24 Q1: -82595.1% Operating margin (TTM), FY24 Q2: -87078.5% Operating margin (TTM), FY24 Q3: -93722.5% Operating margin (TTM), FY24 Q4: -99018.5% Operating margin (TTM), FY25 Q1: -111591.1% Operating margin (TTM), FY25 Q2: -121831.1% Operating margin (TTM), FY25 Q3: -463.5% Operating margin (TTM), FY25 Q4: -512.9% Operating margin (TTM), FY26 Q1: -543.9% Operating margin (TTM), FY26 Q2: -569.7% -569.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -66869.7%
FY23 Q4 -81035.0%
FY24 Q1 -82595.1%
FY24 Q2 -87078.5%
FY24 Q3 -93722.5%
FY24 Q4 -99018.5%
FY25 Q1 -111591.1%
FY25 Q2 -121831.1%
FY25 Q3 -463.5%
FY25 Q4 -512.9%
FY26 Q1 -543.9%
FY26 Q2 -569.7%
FCF margin (TTM) Viridian Therapeutics, Inc.\de
-150000% -100000% -50000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -52245.8% FCF margin (TTM), FY23 Q4: -58938.9% FCF margin (TTM), FY24 Q1: -58403.8% FCF margin (TTM), FY24 Q2: -58618.1% FCF margin (TTM), FY24 Q3: -65374.8% FCF margin (TTM), FY24 Q4: -77096.0% FCF margin (TTM), FY25 Q1: -92829.8% FCF margin (TTM), FY25 Q2: -101507.9% FCF margin (TTM), FY25 Q3: -461.0% FCF margin (TTM), FY25 Q4: -390.8% FCF margin (TTM), FY26 Q1: -428.4% FCF margin (TTM), FY26 Q2: -471.0% -471.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -52245.8%
FY23 Q4 -58938.9%
FY24 Q1 -58403.8%
FY24 Q2 -58618.1%
FY24 Q3 -65374.8%
FY24 Q4 -77096.0%
FY25 Q1 -92829.8%
FY25 Q2 -101507.9%
FY25 Q3 -461.0%
FY25 Q4 -390.8%
FY26 Q1 -428.4%
FY26 Q2 -471.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 5 6 6 3 4 8 4 1 3 2 0 0 71 71
Gross profit 3 3 3 1 — — — — — — — — — —
EBITDA −0 −7 −11 −17 −26 −33 −42 −110 −80 −134 −254 −298 −363 −405
Operating income −0 −7 −11 −17 −27 −33 −42 −110 −80 −134 −254 −299 −363 −405
Net income −2 −8 −11 −17 −27 −33 −42 −111 −79 −130 −238 −270 −343 −387
Diluted EPS −$2751.75 −$787.50 −$315.30 −$423.15 −$20.70 −$16.50 −$20.04 −$31.13 −$6.66 −$4.05 −$5.31 — — —
Growth (year on year)
Revenue — +18.1% −12.0% −39.1% +15.1% +109.5% −46.8% −76.5% +182.2% −40.2% −82.3% −3.8% +>999% +>999%
Margins
Gross margin 49.4% 48.1% 56.7% 26.7% — — — — — — — — — —
EBITDA margin −0.9% −103.7% −192.8% −478.7% −655.1% −391.2% −934.6% <−999% <−999% <−999% <−999% <−999% −512.3% −569.0%
Operating margin −3.6% −105.9% −196.1% −488.6% −662.8% −394.5% −941.0% <−999% <−999% <−999% <−999% <−999% −512.9% −569.7%
Net margin −39.3% −121.7% −198.5% −496.8% −662.3% −390.0% −938.6% <−999% <−999% <−999% <−999% <−999% −483.6% −544.1%
Free-cash-flow margin −21.4% −38.2% −123.0% −431.6% −709.8% −325.4% −810.1% <−999% <−999% <−999% <−999% <−999% −390.8% −471.0%
Cash flow
Cash from operations −1 −2 −7 −15 −28 −27 −36 −30 −55 −94 −184 −232 −276 −333
Capital spending 0 0 0 0 0 0 0 0 0 1 1 1 0 2
Free cash flow −1 −2 −7 −15 −28 −27 −36 −30 −55 −95 −185 −233 −277 −335
Stock-based pay — 4 3 0 2 4 4 4 14 20 67 42 44 54
Free cash flow after stock pay — −7 −10 −15 −31 −31 −40 −33 −69 −114 −252 −275 −321 −389
Balance sheet
Cash 0 5 21 22 47 33 25 46 42 156 103 100 212 165
Total debt 0 0 0 5 10 12 12 0 0 5 20 21 50 242
Net debt (negative = net cash) −0 −5 −21 −17 −37 −20 −13 −46 −42 −151 −83 −79 −162 77
Diluted shares — — — — 1m 2m 2m 4m 12m 32m 45m — — —
Returned to shareholders
Buybacks — — — 0 — — — — — — — — — —
Total returned — — — 0 — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · June 30, 2026
What it owns · $1.1bn
Short-term assets $1.1bnLonger-term assets $16m
What it owes, and who funded it · $1.1bn
Short-term liabilities $64mLonger-term liabilities $371mShareholders' equity $662m
  • Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $64m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.1bn short-term assets against $371m of longer-dated liabilities.
  • More cash than debt $165m of cash against $242m of debt.
  • Debt below 40% of shareholders' equity Debt is 37% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 37% over five years.
  • A year's operating cash flow covers at least 20% of debt −$333m of operating cash flow against $242m of debt.
  • Operating profit covers interest at least five times over Operating income of −$405m against $16m of interest.

From Viridian Therapeutics, Inc.\de's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
456.5%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated VRDN WVE CGEN RXRX CYTK ASMB Median
Revenue, last 12 months $71m $71m $73m $68m $68m $75m $56m
Revenue growth, last 12 months >999% 202.3% 161.1% 56.2% −21.1% 125.1% 12.6%
Revenue growth, 3-year average 264.4% 20.7% 302.6% 12.9% 89.5% −3.3% 13.7%
Revenue growth, latest quarter 278.7% 72.9% — 258.5% −57.1% 38.9% 10.2%
Gross margin 54.5% — 87.3% 29.2% — — 82.9%
Operating margin −569.7% −320.9% 43.1% −725.4% <−999% −11.8% −189.4%
Operating margin, 3-year average <−999% −256.4% −255.7% −995.4% <−999% −126.0% −363.5%
Net margin −544.1% −296.9% 48.6% −697.1% <−999% −0.1% −169.8%
Cash from operations / revenue −468.7% −291.9% 43.5% −455.1% −820.8% −51.4% −168.0%
Free-cash-flow margin −471.0% −293.8% 43.1% −458.0% −858.2% −51.5% −162.4%
Free-cash-flow margin, 3-year average <−999% −148.0% −216.6% −664.1% <−999% −35.8% −310.0%
Stock pay / revenue 75.4% 52.8% 2.6% 129.4% 188.1% 8.9% 20.0%
Change in share count 42.0% 20.2% 4.8% 32.7% 4.9% 50.8% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 23220.3% 12.6% 2 of 172
Change in growth rate Growth -162.5pp -0.1pp 163 of 172
Operating margin Profitability -569.7% -189.4% 123 of 175
Net margin Profitability -544.1% -157.3% 126 of 180
Free-cash-flow margin Cash generation -471.0% -145.4% 129 of 176
Stock pay as % of revenue Cash generation 75.4% 19.2% 130 of 179
Long-term debt as % of assets Balance sheet 22.1% 20.6% 43 of 78

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $70M 98.8% —
Collaboration $849,000 1.2% ▲ 181.1%

From Viridian Therapeutics, Inc.\de's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.5B
Institutions reporting
213
Shares held vs prior quarter
▲ 21.1%
Positions opened / closed
45 / 54

Top buyers and sellers, Q2 2026: 140 institutions bought and 104 sold ; the biggest buyer was Kynam Capital Management, LP (+4.1M shares) and the biggest seller Citadel Advisors LLC (−2.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $305M 16.6M 12.2% ▲ 8.0%
Blackrock, Inc. $157M 8.6M 6.3% ▲ 9.2%
Bellevue Group AG $124M 6.7M 4.9% ▲ 0.1%
Paradigm Biocapital Advisors LP $124M 6.7M 4.9% ▲ 113.5%
Kynam Capital Management, LP $119M 6.5M 4.7% ▲ 175.6%
State Street Corp $113M 6.1M 4.5% ▲ 31.1%
Price T Rowe Associates Inc $106M 5.7M 4.2% ▲ 79.3%
Fairmount Funds Management LLC $93.5M 5.1M 3.7% ▲ 30.1%
Vanguard Capital Management LLC $84.1M 4.6M 3.4% ▲ 9.8%
Deep Track Capital, LP $66M 3.6M 2.6% ▲ 157.7%
Venrock Adviser, LLC $59.8M 3.3M 2.4% ▼ 16.1%
Wellington Management Group LLP $57.5M 3.1M 2.3% ▲ 1.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Viridian Therapeutics, Inc.\de's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $20M 1 trade by 1 insider, last 12 months Insider sales History → $418,990 3 trades by 1 insider · 0% under pre-set plans
Net ▲ $19.6M net buying
Insider Date Trade Shares Price Value
Tousignant Jennifer Chief Legal Officer August 19, 2026 Sell 4,212 $24.50 $103,194
Tousignant Jennifer Chief Legal Officer August 19, 2026 Sell 10,000 $24.50 $245,000
Fairmount Healthcare Fund Ii L.P. Director May 11, 2026 Buy 1,176,470 $17.00 $20M
Tousignant Jennifer Chief Legal Officer December 31, 2025 Sell 2,272 $31.16 $70,796

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 5, 2026
  • February 26, 2026
  • November 5, 2025
  • October 21, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Viridian Therapeutics, Inc.\de was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Viridian Therapeutics, Inc.\de in brief

What does Viridian Therapeutics, Inc.\de do?
Viridian Therapeutics, Inc.\de is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Viridian Therapeutics, Inc.\de's stock ticker?
Viridian Therapeutics, Inc.\de trades under the ticker VRDN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Viridian Therapeutics, Inc.\de's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Viridian Therapeutics, Inc.\de reported revenue of $71.1M, 23220.3% higher than a year earlier, according to its SEC filings.
What is Viridian Therapeutics, Inc.\de's free cash flow?
Viridian Therapeutics, Inc.\de's free-cash-flow margin is -471.0% of revenue over the trailing twelve months, ranking 129 of the 176 biotechnology companies we cover.
Who are Viridian Therapeutics, Inc.\de's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Bellevue Group AG. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Viridian Therapeutics, Inc.\de's market cap?
On December 29, 2023, Viridian Therapeutics, Inc.\de's market capitalisation was about $975M and net debt of -$82.6M. Market figures come from third-party market data and may be delayed.
How much debt does Viridian Therapeutics, Inc.\de have?
Viridian Therapeutics, Inc.\de's debt-to-equity ratio is 36.6%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Viridian Therapeutics, Inc.\de's competitors?
In our Biotechnology peer group, the companies closest to Viridian Therapeutics, Inc.\de are Wave Life Sciences, Inc., Compugen LTD, Recursion Pharmaceuticals, Inc., Cytokinetics Inc and Assembly Biosciences, Inc. The side-by-side comparison below sets their revenue, margins and growth against Viridian Therapeutics, Inc.\de's.
Are insiders buying or selling Viridian Therapeutics, Inc.\de stock?
Over the last 12 months, Viridian Therapeutics, Inc.\de's directors and officers reported 1 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
When is Viridian Therapeutics, Inc.\de's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Viridian Therapeutics, Inc.\de announces its own schedule.